Telomere length (TL) has been associated with outcome in chronic lymphocytic leukemia (CLL). This extensive analysis assess TL on 401 CLL patients subdivided in one cohorts of patients used as learning (191 patients) and one as blinded validation series (210 patients). A TL cutoff of 5000 bp was chosen by receiver operating characteristic (ROC) analysis and Youden’s index in the learning series. In this series,TLp5000 bp was independently associated to a worse outcome for both overall survival (OS; 105.5 vs 281 months, Po0.001) and treatment-free survival (TFS; 24.6 vs 73 months, Po0.001).In the blinded validation series, TLp5000 bp was confirmed as an independent outcome predictor for OS (79.8 vs not reached, Po0.001) and TFS (15.2 vs 130.8 months, Po0.001). Moreover, TLp5000 bp independently predicted the risk of Richter’s syndrome (5-year risk: 18.9 vs 6.4%, P¼0.016). Within CLL subsets defined by biological predictors, TL consistently identified patient subgroups harboring unfavorable prognosis. These results demonstrate that TL is a powerful independent predictor of multiple outcomes in CLL, and contributes to refine the prognostic assessment of this disease when utilized in combination with other prognostic markers. We thus believe that this prognostic biomarker has the potential for a more widespread use in CLL.

Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia

LOBETTI BODONI, CHIARA;GENUARDI, ELISA;MONITILLO, LUIGIA;DRANDI, Daniela;ROCCI, Alberto;FERRERO, SIMONE;BERNOCCO, Elisa;MASSAIA, Massimo;TARELLA, Corrado;BOCCADORO, Mario;LADETTO, Marco
2009

Abstract

Telomere length (TL) has been associated with outcome in chronic lymphocytic leukemia (CLL). This extensive analysis assess TL on 401 CLL patients subdivided in one cohorts of patients used as learning (191 patients) and one as blinded validation series (210 patients). A TL cutoff of 5000 bp was chosen by receiver operating characteristic (ROC) analysis and Youden’s index in the learning series. In this series,TLp5000 bp was independently associated to a worse outcome for both overall survival (OS; 105.5 vs 281 months, Po0.001) and treatment-free survival (TFS; 24.6 vs 73 months, Po0.001).In the blinded validation series, TLp5000 bp was confirmed as an independent outcome predictor for OS (79.8 vs not reached, Po0.001) and TFS (15.2 vs 130.8 months, Po0.001). Moreover, TLp5000 bp independently predicted the risk of Richter’s syndrome (5-year risk: 18.9 vs 6.4%, P¼0.016). Within CLL subsets defined by biological predictors, TL consistently identified patient subgroups harboring unfavorable prognosis. These results demonstrate that TL is a powerful independent predictor of multiple outcomes in CLL, and contributes to refine the prognostic assessment of this disease when utilized in combination with other prognostic markers. We thus believe that this prognostic biomarker has the potential for a more widespread use in CLL.
23
6
1062
1072
chronic lymphocytic leukemia; telomere; prognosis; Richter's syndrome; kinetics; Artificial Intelligence; Biomarkers; Cell Transformation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Survival Analysis; Telomere; Predictive Value of Tests; Hematology; Cancer Research; Anesthesiology and Pain Medicine
D Rossi;C Lobetti Bodoni;E Genuardi;L Monitillo;D Drandi;M Cerri;C Deambrogi;I Ricca;A Rocci;S Ferrero;E Bernocco;D Capello;L De Paoli;L Bergui;M Boi;P Omedè;M Massaia;C Tarella;R Passera;M Boccadoro;G Gaidano;M Ladetto
File in questo prodotto:
File Dimensione Formato  
RossiD-LEUKEMIA2009.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 405.75 kB
Formato Adobe PDF
405.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/58357
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 77
social impact